Retatrutide 40mg: research supplier availability in the EU
Also listed as: GLP-3 R, GLP-3, AMP-3 RT, GLP-3 RT, GLP-RT, AMP-3, MA-3RT, AMP-3 R
Comparing 40mg · . Different forms are not interchangeable.
No EU vendor we track stocks Retatrutide 40mg right now.
Retatrutide, also identified as LY3437943, is an investigational agonist at GIP, GLP-1 and glucagon receptors. A peer-reviewed phase 2 trial and a later sponsor-described phase 3 program are different levels of source evidence. Read identity checks and sources ↓ · Research guides ↓
- Category
- Selected package
- Sizes
- Vendors with current prices
- Form at this size
- Use
Filter suppliers by testing, delivery and payment
Filters hide suppliers; the order is always by price. Testing counts the core test categories printed on each supplier’s newest certificate for this exact product. A count is not a quality rating, and vendor claims such as “8x tested” are not used. Destinations and payment methods are those recorded on each supplier’s profile.
What the filters mean
The core 7 are identity, purity, net content, endotoxin, sterility, heavy metals, multi-vial conformity. Identity counts once whether it is shown by mass spectrometry or by HPLC retention time. Sterility counts for a 14-day USP <71> culture or a rapid PCR sterility test, which are labelled apart. Microbial-limit counts and bioburden are not sterility tests. Multi-vial conformity means two or more vials or bottles from one lot measured on the certificate.
Vendors describe batches as “6x”, “7x” or “8x tested” to mean the number of assays on one batch report, and they count differently. Those labels are not used here; only the categories printed on the certificate count.
A supplier without a product-specific certificate is hidden by any testing filter, and so is a certificate that does not state which package size it covers when the supplier sells several. Certificates are vendor documents read by PeptideTech on Oct 7, 2026; the samples are not independently authenticated.
Ships to and payment method use the destinations and methods each supplier publishes, as recorded on its PeptideTech profile. A supplier whose shipping or payment coverage is not recorded is hidden by that filter rather than assumed to qualify. Confirm both at checkout. In stock only hides offers that were out of stock or stale when last checked.
Where to buy Retatrutide for research
Compare 0 tracked suppliers. Cards show the 40mg price where the supplier lists it in stock, and otherwise its cheapest other size, labelled. Prices exclude delivery and tax. We earn commission through these links; the featured partner is pinned first and the rest are ordered by price.
No tracked Retatrutide supplier matches the filters (0 hidden). Reset the filters to compare every supplier.
We earn commission through these links. Supplier cards show the lowest recent in-stock price for each supplier; the featured partner is pinned first and the rest are ordered by price. COA facts are read from each vendor’s own certificates and are not a quality rating. How comparisons work.
No EU vendor we track stocks Retatrutide 40mg right now. Other forms and sizes are compared above. Check each offer’s source date.
Retatrutide 40mg prices by vendor
Retatrutide for sale: price by size
Retatrutide suppliers compared
Research reference
Selected sources reviewed
Retatrutide, also identified as LY3437943, is an investigational agonist at GIP, GLP-1 and glucagon receptors. A peer-reviewed phase 2 trial and a later sponsor-described phase 3 program are different levels of source evidence.[1][2]
Identity checks
“Triple agonist” names the three receptor targets; it does not identify a separate “GLP-3” receptor or authenticate a product sold under that nickname.[1][2]
Published phase 2 evidence; phase 3 sponsor updates
The published randomized phase 2 trial enrolled 338 adults. Lilly’s current information describes an investigational phase 3 development program. Sponsor updates are identified as sponsor information, not substituted for a peer-reviewed paper or regulatory approval.[1][2]
Regulatory context
Drugs@FDA lists no NDA, BLA or ANDA with retatrutide as an active ingredient (names searched: RETATRUTIDE, LY3437943; checked October 7, 2026). Research-labelled Retatrutide listings are not FDA-approved drugs.
Sources: Drugs@FDA active-ingredient search: RETATRUTIDE, LY3437943 · checked
FDA states that retatrutide is not a component of an FDA-approved drug. Lilly describes it as investigational. This review does not infer regulatory status for every country.[3][2]
Supporting sources
- Retatrutide for obesity: a randomized phase 2 trialNew England Journal of Medicine · PubMed record · checked
- What to know about retatrutideEli Lilly and Company · trial sponsor · checked
- FDA concerns with unapproved GLP-1 drugs used for weight lossU.S. Food and Drug Administration · checked
Research searches — not supporting citations
Search results may include unrelated records. A search link does not establish that a matching study exists.
These selected sources describe named substances and studied formulations. They do not authenticate a supplier, a certificate of analysis or the contents of a particular lot, and do not provide instructions for use. “Healing” and other catalogue categories are navigation labels, not evidence of efficacy or treatment recommendations.
Retatrutide research and reading
Read the evidence, identity checks and limitations alongside the catalogue. Research findings do not verify a vendor’s product or establish suitability for personal use.
October 2026 peptide price report: 86 exact-package comparisons
A retained 2 October snapshot of tracked US supplier prices, with six exact vial examples, source-date ranges and downloadable CSV, JSON and chart.
Published Oct 2, 2026Retatrutide vs tirzepatide vs semaglutide: mechanisms and evidence
Compare receptor targets, regulatory context and the studies that can—and cannot—support a fair comparison of these three molecules.
Updated Sep 17, 2026Retatrutide: what the research shows and its approval status in 2026
A dated guide to retatrutide’s three receptor targets, peer-reviewed results, newer trial announcements and the limits of current evidence.
Updated Sep 17, 2026Retatrutide price history
Actual source observations from the last 14 days, shown separately by supplier, package and currency. Missing days are not filled in. The first refresh can preserve an earlier recorded price; it does not establish a daily price history.
No observation history has been recorded for this selection yet. Current offer dates are shown in the price table.
Save Retatrutide
Bookmark this product in your browser. To keep a particular supplier, size and form, use “Save offer” beside a price. Neither feature sends alerts or creates a subscription.
Is Retatrutide legal? Research-use status
This page compares research-labelled listings for Retatrutide. A listing or a European Union price does not establish authorization for human use or permission to import, possess or supply a product in a particular jurisdiction. Consult the cited regulatory sources and the rules for the actual product and destination. PeptideTech does not sell products or provide medical advice.
FDA states that retatrutide is not a component of an FDA-approved drug. Lilly describes it as investigational. This review does not infer regulatory status for every country.
Retatrutide storage and handling (research context)
Follow the manufacturer’s current product- and batch-specific storage instructions and safety data sheet for Retatrutide. The catalogue does not verify temperature stability, sterility or a preparation method. Do not transfer handling instructions between different forms, concentrations or suppliers.
Reconstitution calculator →Retatrutide price: questions
Automated price sources are scheduled daily; other sources are checked manually. Check the offer's last successful source timestamp. A code is shown when it is attached to an offer or affiliate link. The displayed price includes a discount only when that code is cart-verified and the discounted price is explicitly recorded; otherwise it is the vendor's listed price. Prices exclude shipping. Stock status is captured at the same time. Rankings are by displayed price, except that the labelled featured partner, LA Peptides, is pinned first; “Cheapest” always marks the lowest price. PeptideTech earns a commission when you buy through a link.
Full method →Compare Retatrutide with other research products
Compare package prices and forms; distinct compounds are not interchangeable.
Retatrutide vs Tirzepatide: prices and packagesRetatrutide vs Semaglutide: prices and packagesRetatrutide vs Tesamorelin: prices and packagesMazdutide vs Retatrutide: prices and packagesRetatrutide vs Survodutide: prices and packagesCagrilintide vs Retatrutide: prices and packagesRetatrutide vs Sermorelin: prices and packagesAll research product comparisons